78.2K
Downloads
56
Episodes
Written by expert consultants and clinical scientists currently practising in the UK, the BSH Guidelines provide up-to-date evidence-based guidance on the diagnosis and treatment of haematological diseases. Self accreditation Listen to two podcasts and earn one CPD point via self-accreditation Join our Guidelines Newsletter to be notified when new guidelines/good practice papers are published by going into your members account under MyBSH. Non members can email bshguidelines@b-s-h.org.uk to sign up for updates.
Episodes
Tuesday Nov 21, 2023
Tuesday Nov 21, 2023
The objective of this guideline is to provide healthcare professionals with clear guidance on the diagnosis and management of patients with mantle cell lymphoma.
Wednesday Aug 02, 2023
Wednesday Aug 02, 2023
This Good Practice Paper podcast provides recommendations for the diagnosis, risk stratification and management of the monoclonal gammopathy of undetermined significance (MGUS). It describes the recently recognised entity of the monoclonal gammopathy of clinical significance (MGCS), and recommends how it should be managed. The potential for targeted population screening for MGUS is also discussed.
Wednesday Jul 12, 2023
Wednesday Jun 07, 2023
Wednesday Jun 07, 2023
Haematological management of major haemorrhage: A podcast recording of a conversation between Prof Simon Stanworth and Dr Heidi Doughty.
Friday May 26, 2023
Friday May 26, 2023
A BSH Guideline on the Anticoagulant management of pregnant individuals with mechanical heart valves presented by Dr Will Lester.
Wednesday Dec 21, 2022
Wednesday Dec 21, 2022
Guideline session at EHA Conference 2022 on The Use of Next-generation Sequencing in the Diagnosis of Rare Inherited Anaemias: A Joint BSH/EHA Good Practice Paper
Thursday Dec 08, 2022
Thursday Dec 08, 2022
- Synchronous CNS and systemic lymphoma at initial presentation (treatment-naïve; TN-SCNSL),
- CNS relapse without recurrent systemic lymphoma (relapsed isolated CNS lymphoma; RI-SCNSL).
- Relapsed concomitant systemic and CNS disease following treatment for systemic lymphoma (RC-SCNSL).
CNS lymphoma (CNSL) is associated with inferior outcomes, which may be attributed to several factors: poor CNS penetrance of chemotherapeutics, including RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone),1 impaired neurocognitive function and patient performance status (PS) contributing to increased treatment toxicity,2, 3 and recurrent genetic aberrations conferring treatment resistance.4-6 The rarity and heterogeneity of SCNSL also limits the evidence base for treatment recommendations, with poor outcomes potentially attributable at least in part to lack of optimised treatment protocols.
This good practice paper focuses on diffuse large B-cell lymphoma (DLBCL), the most common SCNSL subtype. It covers diagnostic and therapeutic aspects of care for the three SCNSL scenarios and multiply relapsed SCNSL. Treatment recommendations are framed by patient fitness and treatment intent.
Monday Nov 28, 2022
Monday Nov 28, 2022
This guideline updates and widens the scope of the previous British Society for Haematology (BSH) Clinical guidelines for testing for heritable thrombophilia1 to include both heritable and acquired thrombophilia.
The term thrombophilia is generally used to describe hereditary and/or acquired conditions associated with an increased predisposition to thrombosis. Heritable thrombophilia refers to genetic disorders of specific haemostatic proteins. These guidelines focus only on the factors that are identified from laboratory testing and therefore exclude disorders such as cancer, inflammatory conditions and obesity that are associated with thrombosis through multiple mechanisms.
Friday Aug 26, 2022
Friday Aug 26, 2022
Audio commentary from Dr Mike Dennis on the good practice paper - management of older patients with frailty and acute myeloid leukaemia.
Tuesday Jul 19, 2022